|
|
| | Diridavumab Basic information |
| Product Name: | Diridavumab | | Synonyms: | Diridavumab;Research Grade Diridavumab(DVV03801);Research Grade Diridavumab;Diridavumab (anti-HA) | | CAS: | 1393659-46-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Diridavumab Structure]() |
| | Diridavumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Diridavumab Usage And Synthesis |
| Uses | Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1]. | | in vivo | Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; BALB/c mice with H2 influenza virus) protects mice against lethal H2 influenza virus in a dose-dependent manner[1]. | Animal Model: | BALB/c mice with H2 influenza virus[1] | | Dosage: | 1.7, 5, or 15 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Prevented mortality and decreased the percent weight loss.
Decreased viral load, altered antigen distribution, and reduced the severity of airway inflammation.
|
| | References | [1] Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17. DOI:10.1128/JVI.01603-17 |
| | Diridavumab Preparation Products And Raw materials |
|